Engineering Extracellular Vesicles for Cardiovascular Disease Treatment
Author Information
Author(s): Fu Enze, Pan Kai, Li Zongjin
Primary Institution: Nankai University, Tianjin, China
Hypothesis
Can engineered extracellular vesicles (EVs) serve as effective targeted therapeutics for cardiovascular diseases (CVDs)?
Conclusion
Engineered EVs show promise as novel therapeutic agents for CVDs by enhancing targeted delivery and modulating disease processes.
Supporting Evidence
- EVs can carry therapeutic molecules that promote tissue repair and reduce inflammation in cardiovascular diseases.
- Multiomics analyses have identified key proteins and RNAs in EVs that can serve as biomarkers and therapeutic targets.
- Engineered EVs can enhance drug delivery efficiency and targeting capabilities for treating heart conditions.
Takeaway
Scientists are working on tiny particles called extracellular vesicles that can help treat heart diseases by delivering medicine directly to the right places in the body.
Methodology
The review integrates findings from multiomics analyses of EVs and discusses engineering strategies to enhance their therapeutic potential.
Potential Biases
Potential risks include variability in EV populations and their complex cargo, which may affect biological activity.
Limitations
Challenges include large-scale production, standardization, and ensuring the safety and efficacy of EV-based therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website